NCT04947137View on ClinicalTrials.gov

Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept

PHASE2CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

May 27, 2021

Primary Completion Date

January 21, 2022

Study Completion Date

January 21, 2022

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tc99m tilmanocept

Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Trial Locations (7)

16635

Altoona Center for Clinical Research, Duncansville

33014

San Marcus Research Clinic, Miami Lakes

33157

Innovation Medical Research Center, Palmetto Bay

45429

Kettering Medical Center, Kettering

74137

Essential Medical Research, Tulsa

77598

Tranquility Research, Webster

78215

Sun Research Institute, San Antonio

Sponsors
All Listed Sponsors
lead

Navidea Biopharmaceuticals

INDUSTRY